Nirogacestat, a new desmoid tumor treatment, found to improve outcomes for people with sarcoma

byMemorial Sloan Kettering Cancer CenterCredit:New England Journal of Medicine(2023). DOI: 10.1056/NEJMoa2210140When Dana Avellino, now 36, first noticed a lump near her groin in the

Updated on: January 11,2024

Nirogacestat, a new desmoid tumor treatment, found to improve outcomes for people with sarcoma

byMemorial Sloan Kettering Cancer CenterCredit:New England Journal of Medicine(2023). DOI: 10.1056/NEJMoa2210140When Dana Avellino, now 36, first noticed a lump near her groin in the

Updated on:January 11,2024

The molecules behind metastasis

by Greta Friar,Whitehead Institute for Biomedical ResearchBreast cancer stem cells (red) that have reached the lung begin to divide into clusters that could become metastatic tumors. Credit: Art

Updated on: January 21,2024

The molecules behind metastasis

by Greta Friar,Whitehead Institute for Biomedical ResearchBreast cancer stem cells (red) that have reached the lung begin to divide into clusters that could become metastatic tumors. Credit: Art

Updated on:January 21,2024

Researchers describe a new resistance mechanism

by IDIBELL-Bellvitge Biomedical Research InstituteDue to the treatment with the antibody against Semaphorin 4D (anti-Sema4D), changes occur in the tumor vasculature as well as a decrease in tumor

Updated on: June 08,2024

Researchers describe a new resistance mechanism

by IDIBELL-Bellvitge Biomedical Research InstituteDue to the treatment with the antibody against Semaphorin 4D (anti-Sema4D), changes occur in the tumor vasculature as well as a decrease in tumor

Updated on:June 08,2024

Breast cancer may be likelier to spread to bone with nighttime dim-light exposure

by The Endocrine SocietyCredit: CC0 Public DomainExposure to dim light at night, which is common in today's lifestyle, may contribute to the spread of breast cancer to the bones, researchers

Updated on: March 06,2024

Breast cancer may be likelier to spread to bone with nighttime dim-light exposure

by The Endocrine SocietyCredit: CC0 Public DomainExposure to dim light at night, which is common in today's lifestyle, may contribute to the spread of breast cancer to the bones, researchers

Updated on:March 06,2024

A new combination therapy regimen shows promising results for prostate cancer

by Huntsman Cancer InstituteCredit: CC0 Public DomainTALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progress

Updated on: January 28,2024

A new combination therapy regimen shows promising results for prostate cancer

by Huntsman Cancer InstituteCredit: CC0 Public DomainTALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progress

Updated on:January 28,2024

Tackling resistance to HIF2 drugs with an RNA-based therapy

byUT Southwestern Medical CenterDownregulation of HIF2α by ARO-HIF2 in patient tumor biopsies. Credit: Dr. Payal KapurExpected to be diagnosed in 2% of men and 1% of women in the U.S., kidney ca

Updated on: December 28,2023

Tackling resistance to HIF2 drugs with an RNA-based therapy

byUT Southwestern Medical CenterDownregulation of HIF2α by ARO-HIF2 in patient tumor biopsies. Credit: Dr. Payal KapurExpected to be diagnosed in 2% of men and 1% of women in the U.S., kidney ca

Updated on:December 28,2023

'Double life' of key immune protein reveals new strategies for treating cancer and autoimmune diseases

by NYU Langone HealthCredit: CC0 Public DomainInsights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengt

Updated on: March 20,2024

'Double life' of key immune protein reveals new strategies for treating cancer and autoimmune diseases

by NYU Langone HealthCredit: CC0 Public DomainInsights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengt

Updated on:March 20,2024

News study shows cryoblation 'freeze' treatment works for large breast tumors

by Dennis Thompson and Carole Tanzer MillerKilling off large tumors by freezing them could become an effective means of fighting difficult-to-treatbreast cancer, a new study says.Only 10% of peo

Updated on: March 30,2024

News study shows cryoblation 'freeze' treatment works for large breast tumors

by Dennis Thompson and Carole Tanzer MillerKilling off large tumors by freezing them could become an effective means of fighting difficult-to-treatbreast cancer, a new study says.Only 10% of peo

Updated on:March 30,2024

Researchers study the risk of false positives in colon cancer screening

by IDIBELL-Bellvitge Biomedical Research InstituteCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Colorectal cancer can develop for months without producing any s

Updated on: June 04,2024

Researchers study the risk of false positives in colon cancer screening

by IDIBELL-Bellvitge Biomedical Research InstituteCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0Colorectal cancer can develop for months without producing any s

Updated on:June 04,2024

Experimental AI method boosts doctors' ability to diagnose cancers and precancers of the esophagus

by Delthia Ricks , Medical XpressEndoscopic photographs of lesions in three false-negative patients. Credit:Science Translational Medicine(2024). DOI: 10.1126/scitranslmed.adk5395Artificia

Updated on: August 27,2024

Experimental AI method boosts doctors' ability to diagnose cancers and precancers of the esophagus

by Delthia Ricks , Medical XpressEndoscopic photographs of lesions in three false-negative patients. Credit:Science Translational Medicine(2024). DOI: 10.1126/scitranslmed.adk5395Artificia

Updated on:August 27,2024

Amivantamab-lazertinib ups survival in EGFR-mutated advanced lung cancer

by Elana GotkineFor patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line tre

Updated on: July 08,2024

Amivantamab-lazertinib ups survival in EGFR-mutated advanced lung cancer

by Elana GotkineFor patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line tre

Updated on:July 08,2024

ASCO endorses SIO guideline for integrative Tx in breast cancer

(HealthDay)—The American Society for Clinical Oncology (ASCO) has endorsed the Society for Integrative Oncology (SIO) guideline on the use of integrative therapies during and after breast cancer treat

Updated on: March 30,2024

ASCO endorses SIO guideline for integrative Tx in breast cancer

(HealthDay)—The American Society for Clinical Oncology (ASCO) has endorsed the Society for Integrative Oncology (SIO) guideline on the use of integrative therapies during and after breast cancer treat

Updated on:March 30,2024